tiprankstipranks
Sarepta could be down on patient death in FDA database, says RBC Capital
PremiumThe FlySarepta could be down on patient death in FDA database, says RBC Capital
23d ago
Leerink remains bullish on Sarepta, views EMBARK study results favorably
Premium
The Fly
Leerink remains bullish on Sarepta, views EMBARK study results favorably
25d ago
Sarepta announces topline results from EMBARK study
Premium
The Fly
Sarepta announces topline results from EMBARK study
25d ago
Sarepta wins first phase of Nippon Shinyaku gene-therapy trial
PremiumThe FlySarepta wins first phase of Nippon Shinyaku gene-therapy trial
2M ago
Sarepta completes enrollment in the EMERGENE study of SRP-9003
Premium
The Fly
Sarepta completes enrollment in the EMERGENE study of SRP-9003
2M ago
Arrowhead price target raised to $80 from $60 at H.C. Wainwright
Premium
The Fly
Arrowhead price target raised to $80 from $60 at H.C. Wainwright
3M ago
Sarepta price target lowered to $202 from $205 at Needham
PremiumThe FlySarepta price target lowered to $202 from $205 at Needham
3M ago
Arrowhead price target lowered to $45 from $62 at Piper Sandler
Premium
The Fly
Arrowhead price target lowered to $45 from $62 at Piper Sandler
3M ago
Sarepta price target lowered to $182 from $200 at Piper Sandler
Premium
The Fly
Sarepta price target lowered to $182 from $200 at Piper Sandler
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100